Transport
Grand Strand Regional Medical Center LLC
Grand Strand Regional Medical Center LLC was paid $27.37M by Medicaid between Jan 2018 and Dec 2024, across 217 billing codes. Its largest line is 80053, Comprehensive metabolic panel — 18% of everything it billed.
33Billing provider infoGRAND STRAND REGIONAL MEDICAL CENTER LLC
MYRLTE BEACH, SC 29572
MYRLTE BEACH, SC 29572
33aNPI1083668669assigned 05/19/2006
33bProvider typeAmbulance
28Total paid$27.37M
24GClaims752,404
24DCodes billed217
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Ambulance providers in South Carolina
Rank by total paid#2 of 51
Median peer was paid$630K
This provider vs. median43×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 77,485 | $3.14M | |
| 2019 | 84,356 | $2.98M | |
| 2020 | 88,947 | $2.90M | |
| 2021 | 125,868 | $4.41M | |
| 2022 | 135,321 | $5.12M | |
| 2023 | 129,202 | $5.20M | |
| 2024incomplete | 111,225 | $3.63M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80053 | Comprehensive metabolic panel | 18% | 40,721 | 34,818 | $4.89M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 78,520 | 71,355 | $4.54M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.7% | 23,577 | 22,331 | $1.57M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 5.6% | 7,843 | 7,466 | $1.53M |
| 36415 | Collection of venous blood by venipuncture | 3.9% | 4,750 | 4,413 | $1.06M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.0% | 33,450 | 29,987 | $821K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 2.9% | 2,059 | 1,741 | $792K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.8% | 13,055 | 12,336 | $757K |
| J3490 | Unclassified drugs | 2.2% | 2,519 | 2,336 | $611K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.9% | 7,075 | 5,825 | $533K |
| 87070 | 1.7% | 4,728 | 4,537 | $462K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.6% | 16,084 | 13,341 | $441K |
205 more codes
| 71046 | Radiologic examination, chest; 2 views | 1.5% | 12,240 | $423K |
| 81001 | 1.4% | 24,851 | $370K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.3% | 11,327 | $344K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.2% | 5,755 | $332K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 1.2% | 589 | $318K |
| 81003 | 1.1% | 12,181 | $295K | |
| 73610 | 1.1% | 2,958 | $292K | |
| 86756 | 1.0% | 2,820 | $284K | |
| 82565 | 1.0% | 1,222 | $284K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,072 | $262K |
| 71045 | Radiologic examination, chest; single view | <1% | 14,518 | $242K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 7,499 | $241K |
| 73130 | <1% | 2,336 | $228K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 6,463 | $216K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,095 | $213K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 20,940 | $211K |
| 99285 | Emergency room visit (most serious) | <1% | 7,121 | $209K |
| 73562 | <1% | 2,832 | $208K | |
| 73630 | <1% | 2,956 | $202K | |
| 85027 | <1% | 49,502 | $163K | |
| 73110 | <1% | 1,732 | $155K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 7,518 | $149K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,013 | $149K |
| 12011 | <1% | 835 | $135K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 169 | $130K |
| 10060 | <1% | 894 | $125K | |
| 73030 | <1% | 1,738 | $122K | |
| 12001 | <1% | 846 | $122K | |
| 74018 | <1% | 1,917 | $119K | |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 1,437 | $118K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,141 | $116K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,160 | $113K |
| 81025 | <1% | 16,789 | $112K | |
| 84702 | <1% | 3,522 | $109K | |
| G0378 | Hospital observation service, per hour | <1% | 4,825 | $94K |
| 87210 | <1% | 2,170 | $93K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,545 | $92K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 271 | $87K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,343 | $85K |
| 73080 | <1% | 930 | $75K | |
| 87077 | <1% | 2,227 | $75K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,055 | $73K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 498 | $72K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 546 | $62K |
| 73140 | <1% | 413 | $55K | |
| 72100 | <1% | 982 | $53K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 430 | $50K |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 524 | $49K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,846 | $46K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 8,570 | $43K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 834 | $40K |
| 29125 | <1% | 642 | $39K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 211 | $38K |
| 73502 | <1% | 751 | $35K | |
| 73590 | <1% | 701 | $35K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,098 | $33K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,724 | $33K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 656 | $33K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 17,921 | $33K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,359 | $30K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 756 | $30K |
| 84484 | <1% | 13,931 | $30K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 18,469 | $30K |
| 93971 | <1% | 698 | $29K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 968 | $28K |
| 59025 | Fetal non-stress test | <1% | 1,964 | $28K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 439 | $28K |
| 84703 | <1% | 3,894 | $28K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 14,025 | $27K |
| 73090 | <1% | 448 | $27K | |
| 82803 | <1% | 696 | $24K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,853 | $22K |
| 86850 | <1% | 2,063 | $21K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,364 | $18K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 442 | $17K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 179 | $14K |
| 84439 | <1% | 1,341 | $14K | |
| 76801 | <1% | 411 | $14K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,759 | $13K |
| 76770 | <1% | 115 | $12K | |
| 96376 | <1% | 1,826 | $12K | |
| 93017 | <1% | 391 | $11K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,139 | $11K |
| 76642 | <1% | 148 | $11K | |
| 71250 | <1% | 135 | $11K | |
| 86140 | <1% | 2,006 | $11K | |
| 83690 | <1% | 11,271 | $10K | |
| 85379 | <1% | 1,616 | $9K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,884 | $9K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,345 | $8K |
| 80061 | Lipid panel | <1% | 2,110 | $8K |
| 83880 | <1% | 2,903 | $8K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,891 | $8K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,033 | $8K |
| 72170 | <1% | 684 | $8K | |
| 72040 | <1% | 99 | $7K | |
| 85007 | <1% | 1,309 | $7K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 400 | $7K |
| 70486 | <1% | 213 | $7K | |
| 82042 | <1% | 442 | $6K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,951 | $6K |
| 12002 | <1% | 76 | $6K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 28 | $6K |
| 86900 | <1% | 3,507 | $6K | |
| 76830 | Ultrasound, transvaginal | <1% | 196 | $6K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 551 | $6K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,324 | $5K |
| 80076 | <1% | 70 | $5K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,932 | $5K |
| 73560 | <1% | 138 | $5K | |
| 83605 | <1% | 3,652 | $5K | |
| 83735 | <1% | 13,701 | $5K | |
| 85610 | <1% | 4,746 | $5K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 282 | $5K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,295 | $5K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,596 | $5K |
| 82247 | <1% | 467 | $5K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 271 | $4K |
| 87040 | <1% | 2,835 | $4K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 47 | $4K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 12 | $4K |
| J1815 | Injection, insulin, per 5 units | <1% | 1,007 | $3K |
| 72070 | <1% | 52 | $3K | |
| 73620 | <1% | 86 | $3K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,395 | $3K |
| 71101 | <1% | 47 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 529 | $3K |
| 84100 | <1% | 1,777 | $3K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 708 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,491 | $2K |
| 80074 | <1% | 12 | $2K | |
| C1769 | Guide wire | <1% | 390 | $2K |
| 73552 | <1% | 49 | $2K | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 695 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,874 | $2K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 12 | $2K |
| 73660 | <1% | 12 | $2K | |
| 87186 | <1% | 2,092 | $1K | |
| 15853 | <1% | 27 | $1K | |
| 76820 | <1% | 32 | $1K | |
| 72110 | <1% | 37 | $1K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 13 | $1K |
| 70491 | <1% | 12 | $1K | |
| 72131 | <1% | 26 | $947.95 | |
| 82270 | <1% | 31 | $897.03 | |
| 77066 | Tomosynthesis, mammo | <1% | 12 | $882.62 |
| 82550 | <1% | 98 | $882.15 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 27 | $812.80 |
| 86901 | <1% | 3,507 | $735.17 | |
| 73600 | <1% | 16 | $703.13 | |
| 80047 | <1% | 14 | $695.30 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 977 | $676.24 |
| 76870 | <1% | 13 | $602.97 | |
| 85730 | <1% | 3,208 | $552.31 | |
| 82977 | <1% | 518 | $535.76 | |
| 90714 | <1% | 683 | $484.88 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 5,639 | $464.76 |
| 86308 | <1% | 16 | $426.92 | |
| 88304 | <1% | 428 | $421.66 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,083 | $333.15 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 753 | $325.23 |
| 36000 | <1% | 140 | $274.09 | |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | <1% | 162 | $250.01 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 358 | $249.26 |
| 93975 | <1% | 57 | $218.24 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,203 | $188.00 |
| 84450 | <1% | 375 | $168.55 | |
| 84436 | <1% | 12 | $148.60 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 198 | $39.35 |
| 83540 | <1% | 37 | $35.49 | |
| J2704 | Injection, propofol, 10 mg | <1% | 866 | $33.19 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 29 | $31.42 |
| 90715 | <1% | 38 | $28.69 | |
| 85651 | <1% | 1,304 | $25.52 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 851 | $21.49 |
| 82150 | <1% | 507 | $16.86 | |
| 84460 | <1% | 373 | $14.69 | |
| 84075 | <1% | 365 | $14.47 | |
| 82009 | <1% | 116 | $13.43 | |
| A9270 | Non-covered item or service | <1% | 3,512 | $12.50 |
| 84155 | <1% | 363 | $10.36 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 112 | $6.21 |
| 85045 | <1% | 78 | $5.03 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 72 | $0.24 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 27 | $0.00 |
| 82607 | 0% | 51 | $0.00 | |
| 70498 | 0% | 80 | $0.00 | |
| 41899 | Unlisted procedure, dentoalveolar structures | 0% | 67 | $0.00 |
| 86920 | 0% | 40 | $0.00 | |
| 82728 | 0% | 13 | $0.00 | |
| J0456 | Injection, azithromycin, 500 mg | 0% | 31 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 15 | $0.00 |
| 82746 | 0% | 14 | $0.00 | |
| A9698 | Non-radioactive contrast imaging material, not otherwise classified, per study | 0% | 27 | $0.00 |
| 87205 | 0% | 45 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 23 | $0.00 |
| 00170 | Anesthesia for intraoral procedures, including biopsy | 0% | 151 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 138 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 182 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 55 | $0.00 |
| 82248 | 0% | 12 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 13 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 41 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 63 | $0.00 |
| 83525 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGRACE, ROBERT (CFO)
| Provider | Location | Paid |
|---|---|---|
| Grand Strand Regional Medical Center, LLC | Myrtle Beach, SC | $1.45M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.